Human Metabolome Technologies, Inc.
Supplementary Materials for Q1 FY2027 Earnings
Revenue increased driven by recovery in domestic life science research support services, while overseas remained weak. Overall net sales were 253 million yen, operating loss was -4 million yen, ordinary loss was -0 million yen, and net income attributable to owners of parent was -3 million yen. Q1 was driven by increased domestic projects.
Key Figures
- Net Sales: 253 million yen
- Operating Income: -4 million yen
- Net Income Attributable to Owners of Parent: -3 million yen
AI要約
Earnings Overview
Net sales for this quarter amounted to 253 million yen (significant increase year over year), driven by an increase in large domestic life science research support service contracts. Functional materials development support services (FDS) and bio-manufacturing support services (BMS) decreased due to a seasonal trough, but overall gross profit improved, narrowing operating and ordinary losses. Overseas performance remained weak.
Outlook and Considerations
Continued acquisition of large domestic contracts is important. Balancing recovery in overseas sales with cost management will be key. Note that the supplementary earnings materials may be subject to variability depending on macro trends and progress in R&D.
Human Metabolome Technologies, Inc.
Company overview · Stock price · Financial data · All IR
